Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study

- March 2nd, 2018

Reata Pharmaceuticals (Nasdaq:RETA) a clinical-stage biopharmaceutical company, announced top-line data from the dose-escalation cohorts of the Phase 2 MOTOR trial of omaveloxolone for the treatment of patients with mitochondrial myopathies.  This 12-week, exploratory, dose-ranging trial enrolled 53 patients across six dose levels.  The purpose of the first-in-patient MOTOR trial was to evaluate initial safety, efficacy, … Continued

Reata Pharmaceuticals (Nasdaq:RETA) a clinical-stage biopharmaceutical company, announced top-line data from the dose-escalation cohorts of the Phase 2 MOTOR trial of omaveloxolone for the treatment of patients with mitochondrial myopathies.  This 12-week, exploratory, dose-ranging trial enrolled 53 patients across six dose levels.  The purpose of the first-in-patient MOTOR trial was to evaluate initial safety, efficacy, pharmacokinetics, and pharmacodynamics of omaveloxolone in this patient population.

As quoted in the press release:

The sample size of six to ten patients randomized to omaveloxolone and two to three randomized to placebo for safety controls at each dose level was based upon a traditional dose-escalation design.  The small number of patients at each dose was not expected to fully characterize safety, efficacy, or pharmacodynamics, but rather to inform the data safety monitoring board and Reata of the appropriate dose to select for future study.  The optimal dose of omaveloxolone associated with robust Nrf2 induction and improvement in markers of mitochondrial function was determined to be 160 mg.  At this dose, significant, placebo-corrected improvements were noted in Nrf2 biomarkers.

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply